Changing the Filtration Paradigm
ZERO-5™
PASSIVE particulate capture technology
ZERO-5 Technology uses a patented, passive filtration process that moves a user’s exhale through a five-step series of actions that manipulates airflow and attacks particulates at a molecular level.
MAAP™
ACTIVE Filtration Technology
The next generation of PHILTER products feature integrated Micro Activated Air Purification™ (MAAP) technology that eliminates harmful particulates without the need for filters, making it an ideal at-the-source purification solution for virtually any device that produces harmful airborne particulates.
THE FIRST-EVER BI-DIRECTIONAL VAPORIZOR TECHNOLOGY
A new paradigm in smoking and vaping is coming: Inhale and exhale through one device using a single mouthpiece. With two separate chambers, proprietary PHILTER micro-valving technology is engineered to automatically open or close airways based on an inhale or exhale function. Exhale passes through onboard ZERO-5™ technology, a five-step purification process.
STRONG IP PORTFOLIO
PHILTER maintains a strong focus on building a significant IP presence, currently operating with nine granted utility patents, two design patents, and seven additional patents pending. Our research teams and award-winning product designers hold more than 50 patents granted through previous inventions, with extensive experience in life-saving medical devices, nicotine, and cannabis.
ARTIFICIAL LUNG TESTING
APPARATUS
Philter created the Artificial Lung Testing Apparatus (ALTA) out of the necessity to accurately assess filtration efficacy of the human exhale. The cannabis and nicotine industries had not studied exhale filtration, and did not have equipment to do so. This is the first testing apparatus of its kind and the only one we are aware of.
Get The White Paper
BEYOND CANNABIS: EXTENDING MICROFILTRATION TECHNOLOGY
PHILTER technology currently in use for cannabis is directly applicable to nicotine vape devices, addressing the harmful effects of secondhand smoke at the source of vapor exhale. This technology platform also expands our ability to address other vertical markets where airborne particulate matter is detrimental.
Cannabis
Surgical Smoke
Nicotine
Commercial / Industrial
THE FUTURE OF MICROFILTRATON
Our most advanced innovative technology platform will be ready for commercialization in 2025. We have demonstrated our next generation technologies in the lab and are working on designing MVPs for cannabis and nicotine secondhand smoke applications. These advancements are directly applicable to the surgical smoke and industrial markets. Additional information and a demonstration is available under NDA.
